Novartis continues commitment to go the last mile in effort to eliminate leprosy
Novartis has renewed its pledge with the WHO to work to end leprosy by extending its donation of multidrug therapy medicines to treat leprosy through the year 2020. This five-year agreement includes treatments worth more than USD 40 million and up to USD 2.5 million to support the WHO. August 28, 2015